Moleculin Biotech, Inc. (MBRX)
0.78
+0.03
(+3.99%)
USD |
NASDAQ |
Sep 09, 16:00
0.78
0.00 (0.00%)
After-Hours: 16:07
Moleculin Biotech Enterprise Value : -1.644M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -1.644M |
| September 04, 2026 | -1.930M |
| September 03, 2026 | -2.174M |
| September 02, 2026 | -2.043M |
| September 01, 2026 | -2.355M |
| August 31, 2026 | -2.393M |
| August 28, 2026 | -2.356M |
| August 27, 2026 | -2.080M |
| August 26, 2026 | -2.71M |
| August 25, 2026 | -2.632M |
| August 24, 2026 | -2.644M |
| August 21, 2026 | -2.760M |
| August 20, 2026 | -2.777M |
| August 19, 2026 | -2.909M |
| August 18, 2026 | -2.638M |
| August 17, 2026 | -2.660M |
| August 14, 2026 | -2.623M |
| August 13, 2026 | -2.914M |
| August 12, 2026 | -3.262M |
| August 11, 2026 | -3.810M |
| August 10, 2026 | -3.914M |
| August 07, 2026 | -4.063M |
| August 06, 2026 | -4.236M |
| August 05, 2026 | -4.201M |
| August 04, 2026 | -4.063M |
| Date | Value |
|---|---|
| August 03, 2026 | -3.952M |
| July 31, 2026 | -4.13M |
| July 30, 2026 | 0.272M |
| July 29, 2026 | 2.686M |
| July 28, 2026 | 8.579M |
| July 27, 2026 | 8.579M |
| July 24, 2026 | 8.082M |
| July 23, 2026 | 7.798M |
| July 22, 2026 | 7.94M |
| July 21, 2026 | 8.295M |
| July 20, 2026 | 8.224M |
| July 17, 2026 | 7.94M |
| July 16, 2026 | 8.437M |
| July 15, 2026 | 9.431M |
| July 14, 2026 | 9.076M |
| July 13, 2026 | 8.721M |
| July 10, 2026 | 9.218M |
| July 09, 2026 | 10.35M |
| July 08, 2026 | 9.857M |
| July 07, 2026 | 9.502M |
| July 06, 2026 | 10.07M |
| July 02, 2026 | 11.77M |
| July 01, 2026 | 12.13M |
| June 30, 2026 | 12.84M |
| June 29, 2026 | 9.060M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.635M |
| Total Expenses (Quarterly) | 7.635M |
| EPS Diluted (Quarterly) | -1.402 |
| Earnings Yield | -2.20K% |
| Normalized Earnings Yield | -1904.33 |